HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Wanbury receives USFDA’s OAI classification for Andhra Pradesh facility
Nov-16-2026

Wanbury has received communication from the United States Food and Drug Administration (USFDA) classifying the inspection outcome of the company’s Active Pharmaceutical Ingredient (API) manufacturing facilities situated at Tanuku, Andhra Pradesh, as Official Action Indicated (OAI). The inspection was conducted from July 13, 2026 to July 17, 2026. Based on the company's current assessment, this inspection classification will not have any impact on business continuity or customer supplies of existing products from this facility.

Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.

  RELATED NEWS >>